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ABSTRACT
Purpose: Papillary thyroid carcinoma (PTC) is the most frequent endocrine 
tumor. BRAFV600E represents the PTC hallmark and is targeted with selective 
inhibitors (e.g. vemurafenib). Although there have been promising results in 
clinical trials using these inhibitors, most patients develop resistance and 
progress. Tumor clonal diversity is proposed as one mechanism underlying 
drug resistance. Here we have investigated mechanisms of primary and 
secondary resistance to vemurafenib in BRAFWT/V600E–positive PTC patient-
derived cells with P16-/- (CDKN2A-/-). 
Experimental Design: Following treatment with vemurafenib, we 
expanded a sub-population of cells with primary resistance and characterized 
them genetically and cytogenetically. We have used exome sequencing, 
metaphase chromosome analysis,  FISH and oligonucleotide SNP-microarray 
assays to assess clonal evolution of vemurafenib-resistant cells. Furthermore, 
we have validated our findings by networks and pathways analyses using 
PTC clinical samples. 
Results: Vemurafenib-resistant cells grow similarly to naïve cells but are 
refractory to apoptosis upon treatment with vemurafenib, and accumulate 
in G2-M phase. We find that vemurafenib-resistant cells show amplification 
of chromosome 5 and de novo mutations in the RBM (RNA-binding motifs) 
genes family (i.e. RBMX, RBM10). RBMX knockdown in naïve-cells contributes 
to tetraploidization, including expansion of clones with chromosome 5 
aberrations (e.g. isochromosome 5p). RBMX elicits gene regulatory networks 
with chromosome 5q cancer-associated genes and pathways for G2-M and 
DNA damage-response checkpoint regulation in BRAFWT/V600E-PTC. Importantly, 
combined therapy with vemurafenib plus palbociclib (inhibitor of CDK4/6, 
mimicking P16 functions) synergistically induces stronger apoptosis than 
single agents in resistant-cells and in anaplastic thyroid tumor cells harboring 
the heterozygous BRAFWT/V600E mutation. 
Conclusions: Critically, our findings suggest for the first time that 
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INTRODUCTION
The BRAFV600E mutation is the most frequent 
genetic alteration in papillary thyroid carcinoma (PTC) 
(~60%) and in melanoma (~60-70%) [1, 2]. BRAFV600E 
is a prognostic biomarker of recurrence, tumor 
aggressiveness and mortality in patients with melanoma, 
PTC and hairy cell leukemia [3-10]. It is implicated in 
the tumor aggressiveness of anaplastic/undifferentiated 
thyroid cancer (ATC) [5], a devastating disease that is 
still untreatable. Although highly selective inhibitors 
of BRAFV600E, including the first FDA-approved orally 
available vemurafenib [11] have been tested in clinical 
trials for BRAFV600E–positive cancers with promising 
results [2], tumor primary resistance and development of 
secondary resistance to BRAFV600E inhibitors in patients 
that were initially responding have been reported [12]. 
Different compensatory mechanisms have been shown 
to promote this resistance bypassing pharmacologic 
inhibition of BRAFV600E via the triggering of intracellular 
signaling cascade pathways which lead to reactivation of 
phospho(p)-ERK1/2. Some of these include: elicitation 
of aberrant autocrine loops through the overexpression 
of HER3 receptor [13], over-activation of PI3K/AKT and 
c-Met pathways [14], or JAK/STAT3 signaling [15]. Other 
mechanisms are also linked to eIF4F complex formation 
which is associated with reactivation of ERK1/2 signaling 
[16] or to persistent activation of p-mTOR and p-S6 
ribosomal proteins signaling [17]. Resistance to BRAFV600E 
inhibitors is also mediated by dimerization of aberrantly 
spliced BRAFV600E that dimerize in a RAS-independent 
manner [18]. NRAS mutations, BRAFV600E amplifications, 
MEK1/2 mutations, and overexpression of genes including 
COT, PDGFRB, and others, play a role in the resistance 
to BRAFV600E inhibitors [19]. Also, we have recently 
found that copy number gain of MCL1 (chromosome 1q) 
in metastatic BRAFV600E-PTC cells are associated with 
resistance to vemurafenib treatment [20]. Moreover, we 
showed that the loss of P16 gene (also named P16INK4 or 
CDKN2A, chromosome 9p21) in PTC samples might be 
an important event for metastatic potential [20]. P16 is a 
crucial negative regulator of cell cycle by inhibiting the 
assembly of CDK4/6 complexes and Rb phosphorylation 
during G1 phase [21]. Because of P16 loss in invasive 
thyroid tumor cells, targeting P16 downstream cell cycle 
effectors using CDK4/6 selective inhibitors in combination 
with BRAFV600E inhibitor was rationalized. We decided to 
use palbociclib, a selective inhibitor of CDK4/6 FDA-
approved for treatment of patients with advanced breast 
cancers [22, 23]. Overall, because of the occurrence of 
tumor resistance, new therapeutic options are urgently 
needed against cancers which are resistant to BRAFV600E 
inhibitors, including BRAFV600E-positive metastatic PTC. 
The mechanistic link between vemurafenib treatment 
and the development of resistance in PTC is still not well 
understood. Cancer is an evolutionary system and based on 
cytogenetically diverse clones [24]. Tumor heterogeneity 
might be fundamental for tumor capacity to expand 
resistant clones driven by different selective pressures 
including anti-cancer therapies [25]. Understanding 
thyroid carcinoma cytogenetic heterogeneity and genomic 
alterations emerging during therapy with BRAFV600E 
inhibitors is crucial to improving clinical studies and will 
help investigate mechanisms of tumor progression. We 
selected vemurafenib-resistant BRAFWT/V600E-positive and 
P16-/- PTC patient-derived cells, assessed their cytogenetic 
and genomic profiles, and validated the therapeutic 
efficacy of combined treatment with vemurafenib plus 
palbociclib to efficiently target vemurafenib-resistant cells. 
Our study proposes a novel strategy to treat BRAFV600E-
positive invasive PTC resistant to BRAFV600E inhibitors.
RESULTS
Model of vemurafenib resistance in PTC 
patient-derived cells harboring the heterozygous 
BRAFV600E mutation and with biallelic deletion of 
P16 (P16-/-)
Here, we have developed a new model (Figure 
1A) to investigate primary and secondary resistance to 
vemurafenib using the human spontaneously immortalized 
KTC1 cells derived from the pleural effusion from a 
recurrent and RAI refractory PTC patient. Uniquely, KTC1 
cells are the only PTC patient-derived cells, to the best of 
our knowledge, which harbor with heterozygous status (as 
occurs in PTC samples with BRAFV600E) the constitutively 
active mutant kinase BRAFV600E [20]. Therefore, these 
cells represent a helpful preclinical model for therapeutics 
validations and for investigating mechanisms of resistance 
to BRAFV600E inhibitors for human aggressive/refractory 
PTC. Additionally, these cells show biallelic deletion of 
P16 (chromosome 9p) (Figure 1B-1D, Supplementary 
Table 1) and TP53WT. They also have copy number 
neutral loss of heterozygosity on chromosome 2p, 2q and 
7q (Supplementary Table 1) and gain of chromosome 
targeting BRAFWT/V600E and CDK4/6 represents a novel therapeutic strategy 
to treat vemurafenib-resistant or vemurafenib-naïve radioiodine-refractory 
BRAFWT/V600E-PTC. This combined therapy could prevent selection and 
expansion of aggressive PTC cell sub-clones with intrinsic resistance, 
targeting tumor cells either with primary or secondary resistance to BRAFV600E 
inhibitor.
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Figure 1: Model of primary resistance to vemurafenib using PTC patient-derived cells harboring the heterozygous 
BRAFV600E mutation and with P16 (CDKN2A) deletion. A. KTC1 cells are spontaneously immortalized cell derived from the 
pleural effusion of a BRAFV600E positive recurrent papillary thyroid carcinoma (PTC). B. Probe design for the detection of P16 (CDKN2A) 
by fluorescence in situ hybridization (FISH) in KTC1 cells. C. FISH analysis for the detection of P16 (CDKN2A) gene in KTC1 cells. D. 
Microarray analysis of KTC1 cells (pink). Zoom in view of the CDKN2A gene region of chromosome 9 showing the biallelic deletion of 
9p21. The larger 3.0 Mb deletion on one chromosome 9 takes out the CDKN2A gene and the entire segment covered by the orange FISH 
probe, while the smaller 531 kb deletion also results in deletion of CDKN2A but leaves intact a small portion of the region covered by 
the FISH probe. This explains why a single small red CDKN2A signal was detected by FISH. All above results were validated by two 
independent replicate measurements. E. Phase contrast images of KTC1 cells treated with 10 µM vemurafenib or DMSO (vehicle) for 48 
hours (hrs) show sub-population of cells resistant to treatment (arrowheads). These results were validated at least by three independent 
replicate measurements. F. Growth curve based on KTC1 cell count shown as fold change (FC) in the presence of 10 µM vemurafenib or 
vehicle (DMSO). Angular coefficient (m) values between 0 and 2 days (m1); between 2 and 7 days (m2) are shown: cell death rate was 
significantly reduced by 6.8-folds beyond 2 days by vemurafenib treatment. These data represent the average ± standard deviation (error 
bars) of four independent replicate measurements (*p < 0.05, **p < 0.01, ***p < 0.001). G. Representative western blot analysis of KTC1 
cells treated with 10 µM vemurafenib at the indicated time points shows that phospho(p)-ERK1/2 protein expression levels are not reduced 
in surviving cells compared to vehicle-treated cells. These results were validated at least by three independent replicate measurements. 
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5p (which includes hTERT –human telomerase reverse 
transcriptase- gene) and 17p (Supplementary Table 1). Our 
findings indicated that vemurafenib blocked orthotopic 
KTC1 tumor growth in an early intervention model but 
tumor size was not reduced over time suggesting primary 
tumor resistance [20]. Here we found that most naïve 
cells died upon treatment within 48-96 hours (Figure 
1E). However, the surviving cells showed a significantly 
reduced cell death rate on longer time points (Figure 
1F, angular coefficients ‘m1’ at 0-2 days versus ‘m2’ at 
2-7 days upon vemurafenib treatment) and rebound in 
phospho(p)ERK1/2 protein levels (Figure 1G), indicating 
that the few surviving cells could have intrinsic (primary) 
resistance. As the antitumor activity of BRAFV600E 
inhibitors requires near-complete inhibition of ERK1/2 
activation, minimal reactivation of ERK1/2 signaling 
might lead to tumor progression. Reactivation of ERK1/2 
phosphorylation has been shown to occur steadily upon 
vemurafenib treatment in human cancer cells [13, 26]. 
We have previously showed dose-response curves (IC50, 
50% maximal inhibitory concentration) for vemurafenib 
in different human thyroid cancer cells [20]. Here, in a 
time course of anti-BRAFV600E therapy using KTC1 cells, 
we have assessed pERK1/2 protein levels as readout of 
BRAFV600E kinase activity inhibition, and we found that 
vemurafenib has an acute effect in the early hours of 
treatment but pERK1/2 is progressively less inhibited 
in the following time points compared vehicle-treated 
control cells (Figure 1G). Additionally, we analyzed 
pERK1/2 protein expression levels in other 4 human 
thyroid carcinoma-derived cell lines, PTC or ATC-derived 
cells, with either heterozygous or homozygous mutation 
for BRAFV600E or with BRAFWT/WT (Supplementary Figure 
1). Interestingly, we observed in heterozygous BRAFV600E 
cell lines (KTC1 and SW1736) increased pERK1/2 protein 
levels from 6 to 12 hours independently of their histologic 
origin of the tumor cell line. Whereas the human thyroid 
carcinoma cells with only BRAFWT (i.e. TPC1) (with no 
BRAFV600E) (Supplementary Figure 1) showed an increase 
in pERK1/2 protein expression levels upon vemurafenib 
treatment when compared to vehicle treatment; this 
result is similar to melanoma cell lines with BRAFWT 
which showed paradoxical phenomenon of ERK/12 
phosphorylation activation by BRAFV600E inhibitors [27].
Vemurafenib treatment selects BRAFV600E-positive 
and P16-/- PTC patient-derived cells clones with 
unchanged growth rate
In order to investigate the mechanisms of primary 
resistance to vemurafenib treatment and understand their 
relationship with the potential occurrence of secondary 
resistance, we have expanded the subpopulation of 
KTC1 cells capable to survive to acute therapeutic doses 
of vemurafenib (Figure 2A). We have selected two 
independent vemurafenib-resistant tumor cells batches by 
applying cycles of high doses of vemurafenib alternated 
by expansion of the surviving cells (Figure 2A). Most 
KTC1 cells died upon treatment with vemurafenib within 
48-96 hours however the few surviving cells (Figure 1E, 
arrows), when biochemically assayed for pERK1/2 levels 
showed no difference between vehicle and vemurafenib 
treatment (Figure 1G), indicating that they have primary 
resistance to vemurafenib. To expand and analyze this 
cell subpopulation with intrinsic primary resistance, 
KTC1 cells were exposed to vemurafenib, and then the 
few surviving cells were expanded without treatment 
(Figure 2A) in order to avoid bias toward the selection 
of secondary mutations which might specifically trigger 
cell cycle progression. When we analyzed vemurafenib-
resistant KTC1 cells for growth following a week-long 
vemurafenib-sustained treatment, we found that these cells 
showed a net increased number over the time but with a 
significantly slower growth rate compared to vehicle-
treated cells (best fitting curves equations: y = 0.0722x + 
1.0444 and y = 0.0513x + 1.0576) (Figure 2B). Instead, 
vemurafenib-naïve cells (Figure 1F) showed a reduction 
of the total cell number as shown by the negative growth 
rate (see Figure 1F, best fitting curve days 0-2: y = 
-0.2959x + 1.3438 and days 2-7: y = -0.0457x + 0.449). 
In addition, when resistant cells (Figure 2B) were exposed 
to the vehicle, they did not show any significant change in 
growth rate compared to vehicle-treated naïve KTC1 cells 
(Figure 1F). Analysis of cell cycle by BrdU (5-bromo-
2-deoxyuridine)/PI (propidium iodide) combined assay 
showed that both resistant cells batches exposed to vehicle 
have a significantly higher cell percentage distributed in 
G2-M phase compared to naïve cells (Figure 2C, 1.51 
and 1.36 fold-change, respectively). In addition to these 
results, we found that cyclin B1, a crucial regulator for the 
transition of cells from G2 to M phase, showed substantial 
increased mRNA expression levels (1.2 fold-changes) in 
the vemurafenib-resistant KTC1 cells compared to the 
vemurafenib-naïve KTC1 cells when exposed to vehicle 
treatment. 
Oligonucleotide-SNP microarray, metaphase 
chromosome and FISH analyses of naïve and 
vemurafenib-resistant thyroid carcinoma cells 
show karyotypic heterogeneity and expansion of 
clones with chromosome 5 aberrations
In order to assess tumor cell heterogeneity 
and clonal evolution, we performed Affymetrix 
oligonucleotide-SNP microarray assay (Figure 3A-
3D), metaphase chromosome analysis (Figure 3E), 
fluorescence in situ hybridization (FISH, Figure 3F), 
and exome sequencing (Supplementary  Tables 2-4) in 
the 2 independent populations of resistant KTC1 cells 
(KTC1Res.1 and KTC1Res.2, Figure 2A) and compared to 
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Figure 2: Clonal selection and expansion of PTC patient-derived cells with BRAFV600E and P16-/- in the presence of 
vemurafenib treatment. A. Experimental model of clonal expansion of KTC1 cells with primary resistance to vemurafenib: two 
independent batches of resistant cells, KTC1Res.1 and KTC1Res.2, were exposed to 10 µM vemurafenib for 12 or 24 weeks, respectively, 
to select vemurafenib-resistant clones. B. Growth curve of KTC1Res.1 and KTC1Res.2 cells treated with 10 µM vemurafenib or vehicle 
(DMSO). Vehicle-treated KTC1Res.1 and KTC1Res.2 cells show similar growth rate compared to KTC1Naive cells (Figure 1F). Vemurafenib-
treated resistant cells grew significantly slower compared to vehicle-treated control cells. Vemurafenib-treated resistant cells grew with a 
constant rate (slope/gradient analysis, m value=+0.07 or =+0.05, respectively) compared to KTC1Naive cells (negative m values reported 
in Figure 1F). These data represent the average ± standard deviation (error bars) of four independent replicate measurements (*p < 0.05, 
**p < 0.01, ***p < 0.001). C. Percentage of cells in G0-G1, S and G2-M phases in KTC1Naive, KTC1Res.1, and KTC1Res.2 when exposed to 
10 µM vemurafenib or vehicle (DMSO) for 48 hrs: vemurafenib treatment induced a significant increase of either naïve or resistant cells 
in S and G2-M phase compared to vehicle-treated cells. Vehicle-treated resistant cells significantly increased in G2-M phase compared to 
vehicle-treated naïve cells (KTC1naïve=6.33±0.78; KTC1Res1=9.53±1.61, p-value=0.023; KTC1Res2= 8.65±1.15, p-value=0.032). These data 
represent the average ± standard deviation (error bars) of two independent replicate measurements (*p < 0.05, **p < 0.01, ***p < 0.001, 
NS=not significant).
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the parental vemurafenib-naive KTC1 cells (KTC1Naive). 
The oligonucleotide-SNP microarray assay identified copy 
number neutral loss of heterozygosity on chromosome 2p, 
2q and 7q and gain of chromosome 5p (Figure 3A-3D) 
and 17p (Figure 3A-3C). These somatic copy number 
variations in vemurafenib-resistant KTC1 cells and naïve 
KTC1 cells were similar (including the biallelic deletion 
of P16) except for the gain of the entire chromosome 5 
detected in the vemurafenib-resistant KTC1 cells but 
not in the naïve KTC1 cells (Figure 3D, Supplementary 
Table 1). Interestingly, no other chromosome acquired 
a copy number variation (gain or loss) in resistant cells. 
The duplication on chromosome 17p, as well as the 2p, 
2q and 7q neutral loss, occurred prior to the verumafenib 
treatment in KTC1Naïve cells and remained unchanged in 
the resistant cells. Furthermore, we found aneuploidy and 
tetrasomy (due to tetraploidy) of chromosome 5 (Figure 
3E-3G, Supplementary Figure 2, Supplementary Table 
1). We confirmed and quantified this result by analyzing 
two hundred interphase nuclei for cell condition by FISH 
(Figure 3F) with probes for chromosome 5, revealing that 
70% and 30% of the KTC1Naïve cells showed diploidy, 
or aneuploidy/tetraploidy, respectively. Specifically, 
KTC1Naïve cells included diverse clones with trisomy of 
chromosome 5, with one or two copies of supernumerary 
isochromosome of the short arm of chromosome 5 (+i5p), 
or clones with tetrasomy due to tetraploidy (Figure 3F-
3G, Supplementary Figure 2, Supplementary Table 1). 
Importantly, the presence of extra chromosomes has been 
reported to lead to genomic instability [28]. Remarkably, 
following the long-term sustained treatment with 
vemurafenib, resistant KTC1 cells reduced the diploid 
clones 1.3-1.7 fold-change and increased the aneuploid/
tetraploid clones 1.5-1.9 fold-change compared to the 
naïve cells. In particular, KTC1Res.1 cells showed 43% 
and 57% diploid or aneuploidy/tetraploidy karyotype, 
respectively, and KTC1Res.2 cells showed 52.5% and 47.5% 
diploid or aneuploidy/tetraploidy karyotype, respectively 
(Figure 3F-3G). 
Vemurafenib-resistant BRAFV600E-PTC patient-
derived cells acquire de novo mutations in RBM 
genes
To further investigate the mechanisms which 
contribute to the survival and expansion of vemurafenib-
resistant KTC1 cells, we also analyzed by exome 
sequencing the occurrence of secondary and somatic 
copy number variations. Exome sequencing is able 
to detect single nucleotide changes and defines with 
precision the allelic fraction of the identified mutation. 
As internal control we verified the mutant BRAFV600E 
allele fraction, and as expected we found that it resulted 
50% (along with 50% of wild type BRAF allele) in both 
naïve and resistant KTC1 cells (Supplementary Table 2). 
More importantly, the exome sequencing analysis after 
appropriate filter application displayed mutations (by 
allelic fraction analysis) in the RBM genes only in the 
vemurafenib-resistant cells but not in the vemurafenib-
naïve cells. In particular, we found an in-frame deletion 
in the RBM10 gene (chromosome X, 1537_1539delGAG, 
E513del) with 87% of allele fraction in the KTC1Res.1 
cells (Supplementary Table 3) and a missense mutation 
in the RBMX gene (chromosome X, 499C>G, P167A) 
with 33.3% of allele fraction in the KTC1Res.2 cells 
(Supplementary Table 4). The RBMX499C>G mutation 
shows protein change as follows: P167A (proline (P) 
to alanine (A)). Proline has major roles in the proper 
tertiary structure folding of proteins. Loss of a proline and 
substitution with the non-polar alanine may be predicted 
to result in potential loss of an important structural motif 
in the RBMX protein RBMX (also named hnRNP-G or 
RBMXP1). RBMX plays an important role to protect 
cells against DNA damage [28] and for chromosome 
segregation [29] and might contribute, therefore, to 
vemurafenib resistance. To test this hypothesis, we 
knocked-down wild-type (WT) RBMX using the most 
efficient shRNA (Figure 4A) among the two tested (data 
not shown) in the naïve KTC1 cells compared to the sh-
control cells. Importantly, silencing of RBMX (sh-RBMX) 
showed an increase of p-AKT protein levels in naïve 
KTC1 cells compared to the sh-control cells when exposed 
to vehicle or single agent treatments (Figure 4B). FISH 
analysis demonstrated that RBMX knockdown resulted 
per se in a modest increase of tetraploidization (9.5% 
in sh-control cells vs. 11.5% in sh-RBMX cells) and in 
a substantial increase (2.6 fold-changes) in tetraploidy in 
the presence of vemurafenib treatment, from 7.5% in the 
sh-control cells to 19.5% in the sh-RBMX cells (Figure 
4C-4D). 
RBM genes elicit regulatory networks with up-
regulated genes in BRAFV600E-PTC compared to 
BRAFWT-PTC clinical samples which are involved 
in tumor survival
In order to understand which pathways are connected 
with wild-type RBM genes in thyroid cancer, we first 
randomly built RBMX and RBM10 gene regulatory 
network (fold-change cutoff: 2; p-value <0.05) using 
human PTC samples from TCGA (The Cancer Genome 
Atlas). We found that only RBMX gene was significantly 
co-expressed with 38 out of 1884 (2%) up-regulated genes 
(Supplementary Table 5) in BRAFV600E-PTC compared to 
BRAFWT-PTC TCGA samples (Figure 5A). Those 38 genes 
are located on different chromosomes (Supplementary 
Table 5). Only 10 out of 38 (26.3%) genes interacted with 
RBMX creating regulatory networks which converge 
on crucial pathways for tumor microenvironment/ECM 
remodeling functions, cell polarity, inflammation and 
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Figure 3: Vemurafenib-resistant PTC patient-derived cells with BRAFV600E and P16-/- show an increased tetraploidy/
aneuploidy and expansion of clones with chromosome 5 amplification. A.-C. Ideogram of an Affymetrix oligonucleotide-SNP 
microarray analysis of the chromosomes landscape of KTC1Naive, KTC1Res.1, and KTC1Res.2 cells showed copy number gain of chromosome 
5 (red box) and on 17p, loss on chromosome 9p and copy number neutral loss of heterozygosity on chromosomes 2 and 7. KTC1Res.1 and 
KTC1Res.2 cells acquire copy number gain of 5q compared to KTC1Naive cells. D. Affymetrix oligonucleotide-SNP microarray analysis with 
zoom in of somatic copy number variations (SCNV) of chromosome 5 in KTC1Naive (pink), KTC1Res.1 (orange) and KTC1Res.1 (blue) cells. 
KTC1Res.1 (2.45 copies) and KTC1Res.2 (2.44) showed extra copies of chromosome 5q compared to the KTC1Naive cells (2 copies). KTC1Naive 
cells showed 3.8 extra copies of 5p (produced by two copies of one 5p isochromosome) in 45% of the cells in the sample. KTC1Res.1 cells 
showed 2.56 copies of chromosome 5p in 44% of the cells and 2 extra copies of 5p (produced by a 5p isochromosome) in 17% of the 
cells in the sample. KTC1Res.2 cells showed 2.78 copies of chromosome 5 in 45% of the cells and 2 extra copies of 5p (produced by a 5p 
isochromosome) in 5.5% of the cells in the sample. All these findings were validated by at least by two independent experiments with 
replicates measurements. E. Clones with respect to chromosome 5 identified in KTC1Naive, KTC1Res.1 and KTC1Res.2 cells. KTC1 cells 
showed karyotype with either diploidy, or aneuploidy or tetrasomy (due to tetraploidy) of chromosome 5. Green and red dots exemplify 
how these karyotypes are visualized by FISH in panel F. F. Chromosome 5 clones assessed by fluorescence in situ hybridization (FISH) 
analysis in KTC1Naive, KTC1Res.1 and KTC1Res.2 cells. Specific probes identify chromosome 5p (green) and 5q (red). G. Quantification of 
chromosome 5 clones detected by FISH in KTC1Naive, KTC1Res.1 and KTC1Res.2 cells. 
Oncotarget84750www.impactjournals.com/oncotarget
Figure 4: RBMX knock-down contributes to tetraploidy in PTC patient-derived cells with BRAFV600E and P16-/- 
treated with vemurafenib. A. Representative western blotting analysis of RBMX knockdown (sh-RBMX) compared to control (sh-
FF) and densitometry quantification (FC=fold change) of RBMX protein levels at 48 hrs post seeding in BRAFV600E-KTC1Naive cells. B. 
Representative western blotting analysis of RBMX, pAKT, tAKT, pERK1/2 and tERK1/2 protein expression levels in KTC1Naive cells with 
RBMX knockdown (sh-RBMX) compared to shRNA control (sh-FF) cells at 48 hrs. These results were validated by two independent 
replicate measurements. C. Fluorescence in situ hybridization (FISH) analysis of KTC1Naive cells with RBMX knockdown compared to 
sh-control cells. D. Quantification of clones by interphase fluorescence in situ hybridization (FISH) analysis in KTC1Naive cells engineered 
to express sh-RBMX or sh-control (shFF). Cells were treated for 48 hrs with either vehicle or 10 µM vemurafenib. These results were 
validated quantifying 200 cells by two independent replicate measurements. 
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immune suppression processes, tumor survival, tumor 
metabolism, cell cycle regulation, and DNA damage-
response (Figure 5A). Two out of 38 (5.2%) up-regulated 
genes are located on chr.5q (Supplementary Table 5) and 
play more specialized biological roles: brain functions 
and endosome-to-lysosome trafficking of membrane (i.e. 
GABRB2), and regulation of protein metabolism for 
glycosylation (i.e. GCNT4). Moreover, since our findings 
showed amplification of chromosome 5 we built RBMX 
and RBM10 gene regulatory network specifically with 
the cancer-associated genes located on chromosome 5p 
(33 genes) (Supplementary Table 6) and 5q (68 genes) 
(Supplementary Table 7) in BRAFV600E-PTC compared 
to BRAFWT-PTC TCGA samples. Twenty-two out of 
1884 (1.1%) were chr.5q differentially expressed cancer-
associated genes significantly up-regulated in BRAFV600E-
PTC compared to BRAFWT-PTC and co-expressed with 
RBMX. Importantly, 9/22 (41%) of cancer-associated 
up-regulated genes on chromosome 5q significantly (p < 
0.05) interacted with RBMX gene (Figure 5B), whereas 
none of the cancer genes on 5p (Supplementary Table 6) 
interacted with RBMX, indicating network specificity. 
Moreover, the pathways emerging from networks between 
RBMX and 5q cancer genes were involved in tumor 
survival and metabolism, G2 and mitosis homeostasis, 
cell cycles checkpoints regulation, chromosomes stability, 
DNA damage-response checkpoints, microenvironment 
homeostasis, extracellular matrix (ECM) organization, 
and regulation of MAPK signaling (Figure 5B). RBM10 
had networks with 8 out of 1884 (0.4%) differentially 
expressed cancer-associated genes on 5q. These genes 
also resulted significantly up-regulated in BRAFV600E-
PTC compared to BRAFWT-PTC and co-expressed with 
RBM10. Three out of 8 (37.5%) genes created significant 
regulatory networks with RBM10 evoking interconnected 
WNT signaling-related pathway (Figure 5C). 
Combined therapy with vemurafenib plus 
palbociclib overcomes primary and secondary 
resistance in BRAFV600E-positive and P16-/- PTC 
patient-derived cells
BRAFV600E-positive PTC patient-derived KTC1 
cells showed deletion of the P16 gene (P16-/-) (Figure 
1B-1D). To determine if the inhibition of BRAFV600E and 
targeting of CDK4/6 (P16 downstream effector) was 
effective against these tumor cells, we tested a therapeutic 
approach using vemurafenib plus palbociclib treatment 
(Figure 6A), two FDA approved drugs for metastatic 
BRAFV600E-positive melanoma and metastatic breast 
cancer, respectively. In order to assess the most effective 
doses of combined therapy with vemurafenib plus 
palbociclib, we treated thyroid tumor cells for 48 hours 
with a matrix of nine different drug doses combinations 
(Figure 6B, Supplementary Figure 3). Our results 
showed that 10 µM vemurafenib plus 10 µM palbociclib 
significantly provided the best therapeutic efficacy 
against thyroid tumor cells (Figure 6B). This combined 
therapy significantly decreased cells number of 13.3, 8 
and 8.6 fold-change compared to vehicle, vemurafenib 
or palbociclib treatments, respectively (Figure 6B, 
Supplementary Figure 3), likely by synergistic effects 
(Figure 6C). Importantly, we found significant induction 
of apoptosis in both vemurafenib-naïve and vemurafenib-
resistant cells when we used this combined therapy as 
shown by annexin V/PI apoptosis analysis (Figure 6E-6F) 
and by the substantial reduction of pro-survival factors 
such as phospho(p)-Rb, pAKT and MCL1 and increase of 
cell death markers (cleaved caspase-3 and cleaved PARP, 
Figure 6D). More importantly, this combined therapy was 
significantly effective to cause apoptosis compared to 
either single agents or vehicle-treated cells (Figure 6E). 
Additionally, we tested the therapeutic efficacy of these 
drugs in advanced/aggressive ATC-derived cells. ATC 
is a deadly disease with a dismal prognosis. ATC cells 
harbored BRAFV600E and showed wild-type P16 status 
(Supplementary Figure 4). They were also effectively 
sensitive to vemurafenib plus palbociclib treatment 
which caused a significant reduction of cell number over 
the time (Supplementary Figure 5), suggesting that this 
therapy can be also used in BRAFV600E-positive ATC 
with wild-type P16. We also found that vemurafenib 
plus palbociclib maintained down-regulation of p-AKT 
(critical pro-survival factor) protein levels when RBMX 
(sh-RBMX) was silenced compared to the single agent 
or vehicle treatments (Figure 4B), suggesting that this 
combined therapeutic approach could have anti-tumor 
survival activity by affecting AKT expression levels 
and subsequently its downstream effectors. Critically, 
this combined therapy substantially reduced the number 
of BRAFV600E-positive and P16-/- tumor cell clones with 
chromosome 5 aberrations (i.e. extra copies of +i5p) 
compared to vehicle-treated cells (from 3.7% or 16.2% to 
0) or more importantly to single agent treatments within 48 
hrs (Table in Figure 6G). Whereas single agent treatments 
did not show robust changes in +5px1 copies, vemurafenib 
treatment decreased +i5px2 extra copies compared to 
vehicle-treated cells (Table in Figure 6G). Collectively, 
our findings indicate that vemurafenib treatment on 
BRAFV600E-positive invasive thyroid carcinoma cells with 
P16-/- acts as a selective pressure favoring the appearance 
of resistant clones with chromosome 5 aberrations and 
RBM genes (e.g. RBMX and RBM10) de novo mutations. 
Importantly, combined inhibition of BRAFV600E and 
CDK4/6 synergistically induces apoptosis in both naïve 
and resistant tumor cells, indicating that the mechanism 
of resistance to vemurafenib requires CDK4/6 pathway 
activation. In summary, this combined therapeutic 
approach results in both effective early treatment 
preventing the selection and expansion of aberrant thyroid 
tumor cell clones with primary resistance, but also as 
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Figure 5: RBM genes regulatory networks with up-regulated genes in BRAFV600E-PTC versus BRAFWT-PTC human 
samples. A. Differential gene expression analysis on BRAFV600E-PTC vs. BRAFWT-PTC human samples (PTC TCGA data base) identified 
1884 genes with p < 0.05 and fold change 2. The co-expression analysis for these genes was performed on the basis of PTC TCGA data 
(interactions with p value <0.05 from correlation test were considered significant) to generate a map of RBMX and RBM10 gene regulatory 
networks. Image shows genes that depict significant interaction with RBMX top pathways of interactive genes regulatory networks. Red 
circles indicate up-regulated genes in BRAFV600E-PTC vs. BRAFWT-PTC samples. B. RBMX gene regulatory networks with chromosome 
5q cancer-associated genes annotated by NCBI using BRAFV600E-PTC vs. BRAFWT-PTC human samples (PTC TCGA data base). The co-
expression analysis for these genes was performed on the basis of PTC TCGA data (interactions with p value <0.05 from correlation test 
were considered statistically significant). For pathways analysis: -Log p value 1.3= p value= 0.05; -log p value 2= p value= 0.01; -log p 
value 3= p value= 0.001; -log P value 4= p value=0.0001. C. RBM10 gene regulatory networks with chromosome 5q cancer-associated 
genes annotated by NCBI using BRAFV600E-PTC vs. BRAFWT-PTC human samples (PTC TCGA data base) (interactions with p value <0.05 
from correlation test were considered statistically significant).
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late intervention on vemurafenib resistant tumors with 
secondary resistance (Figure 6H-6J).
DISCUSSION
PTC is associated with a favorable long term 
survival. However, the subgroups of patients who develop 
distant metastases have a worse prognosis [30]. BRAFV600E 
can be measured in the blood of patients with metastatic 
PTC (e.g. lung metastasis) [31]. Patients with advanced 
BRAFV600E-PTC generally showed partial response to 
BRAFV600E inhibitors [32]. Phase I study of vemurafenib in 
three patients with BRAFV600E-PTC reported that one had 
partial response with reduction of pulmonary target lesions 
by 31%, and the duration of response was 7.6 months 
before the disease progressed in the lungs and bones [33]. 
Therefore, advanced PTC showed partial response to 
vemurafenib and unavoidably relapses as refractory 
carcinomas. Unfortunately, the majority of patients with 
cancer may develop resistance in a short time from the 
initiation of therapy. How metastatic PTC becomes 
resistant to BRAFV600E inhibitors (e.g. vemurafenib) 
remains poorly understood. In this study, we have 
investigated the genetic properties of vemurafenib-
resistant cells in a unique model of heterozygous 
BRAFV600E human thyroid cancer cells established from a 
metastatic pleural effusion of a BRAFV600E-positive 
recurrent PTC patient. Tumor cells have genomic 
instability and often have complex karyotypes with 
numerous chromosomal rearrangements and polyploidy 
(e.g. aneuploidy, tetraploidy). However, KTC1 cells 
showed diploid and aneuploid/tetraploid clones with 
relatively few chromosomal aberrations, representing an 
ideal model to study clonal evolution and occurrence of 
drug resistance. KTC1 cells were exposed to vemurafenib 
to eradicate sensitive cell subpopulations and expand 
resistant clones. We found resistance to vemurafenib in 
tumor cells harboring amplification of chromosome 5 and 
mutations in RBM genes which are fundamental for 
genome stability during cell division [28]. These findings 
could indicate that treatment failure and disease relapse in 
metastatic advanced BRAFV600E-PTC might be linked to 
the selection of aneuploidy/tetraploid cell subpopulations 
with extra copies of chromosome 5. Interestingly, we 
found two independent de novo mutations in the RBM 
gene family (i.e. RBM10 and RBMX) in the vemurafenib-
resistant cells but not in the vemurafenib-naïve thyroid 
tumor cells which did not show measurable allelic 
fractions for these mutations. These genes are involved in 
the regulation of RNA splicing [34] [35] and apoptosis 
[36]. RBM10 is a tumor suppressor that represses Notch 
signaling and cell proliferation [37]. Importantly, RBM10 
has been recently found to be mutated in the aggressive 
and fatal subtypes of thyroid carcinoma, and the overall 
survival of patients with RBM10 mutations was 
significantly poorer compared to those with wild type 
Figure 6: Combined therapy with vemurafenib plus palbociclib overcomes resistance to single agent treatments in 
PTC patient-derived cells with BRAFV600E and P16-/-. A. Diagram of a proposed targeted therapy strategy in human invasive 
thyroid carcinoma cells harboring the heterozygous BRAFV600E mutation and with P16 loss (P16-/-). B. Histogram shows cells number upon 
treatments with vehicle, vemurafenib, palbocilib, or combined therapy vemurafenib plus palbociclib; quantitative analysis was performed 
at 48 hours post-treatments by direct counting of adherent cells. These data represent the average ± standard deviation (error bars) of 
three replicates from two independent measurements. Statistical significance (*p <0.05; **p < 0.01; NS=not significant) was determined 
by one-way analysis of variance (ANOVA) using Tukey’s correction for multiple comparisons. C. Visualization of drug combinations: 
surface plots of naïve KTC1 cells treated vehicle, vemurafenib, palbocilib, or combined therapy vemurafenib plus palbociclib. Each point 
represents the mean of three replicates from two independent measurements. Plots were generated using Combenefit script by MATLAB 
R2017a by applying three methods for combined treatments: Bliss (effect-based approach); Highest Single Agent (HSA) (effect-based 
approach); and Loewe (dose-effect based approach). Level of antagonism or synergism is rapresented by color scale bar. D. Western 
blotting analysis of proteins expression levels at 24 hrs treatment with DMSO (vehicle), vemurafenib, palbocilib and combined therapy 
with vemurafenib plus palbocilib. These results were validated by two independent experiments. E. Quantification of apoptosis by annexin 
V and propidium iodide (PI) dual staining assay in KTC1Naive, KTC1Res.1 and KTC1Res.2 cells at 48 hrs treatment with DMSO (vehicle), 10 
µM vemurafenib, 10 µM palbocilib and combined therapy with 10 µM vemurafenib + 10 µM palbocilib. These data represent the average 
± standard deviation (error bars) of two independent replicate measurements (*p < 0.05, **p < 0.01, ***p < 0.001, NS=not significant). F. 
Representive Annexin V/PI Flow cytometry analysis of KTC1Naive, KTC1Res.1 and KTC1Res.2 cells at 48 hrs treatment with DMSO (vehicle), 
10 µM vemurafenib, 10 µM palbocilib and combined therapy with 10 µM vemurafenib + 10 µM palbocilib. These data are representative 
of three independent replicate measurements (*p < 0.05, **p < 0.01, ***p < 0.001). G. Quantification of cell clones with either diploid or 
chromosome 5 aberrations assessed by interphase fluorescence in situ hybridization (FISH) analysis in KTC1Naive cells treated for 48 hrs 
with vehicle, 10 µM vemurafenib (vemu), 10 µM palbociclib (palbo) or 10 µM vemurafenib plus 10 µM palbociclib. These results were 
validated quantifying 200 cells by two independent replicate measurements. H. KTC1 cells harboring the BRAFV600E mutation and with 
P16 loss show heterogeneous clones which are  diploid, aneuploidy (trisomy of chromosome 5, with one copy (+i5px1) or two copies 
(+i5px2) of isochromosome 5p), or with tetrasomy of chromosome 5 due to tetraploidy. I. Clonal selection and expansion of KTC1 cells 
during sustained treatment with vemurafenib; these selected clones acquire mutations in the RBM genes (e.g. RBMX, RBM10). J. Scheme 
of treatments with vemurafenib and palbociclib: dashed lines indicate that KTC1 cells clones with trisomy or tetrasomy of chromosome 5, 
+i5px1, or RBM mutations are resistant and less responsive to the single agent treatments. Whereas combined therapy with vemurafenib 
plus palbociclib (thick bold lines) significantly induces cell death and overcomes resistance to the single agent treatments by reducing 
clonal expansion of KTC1 cells with chromosome 5 aberrations.
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RBM10 [38], suggesting a role for this gene in thyroid 
tumor aggressiveness and progression. RBMX is a 
regulator for maintenance and centromeric protection of 
sister chromatid cohesion during cell division and for 
chromosomes stability [28, 29]. The karyotype of cancer 
is highly variable and often shows genetic complexity with 
chromosomal instability (e.g. chromosomal loss or gain), 
ranging from hypodiploidy to tetraploidy, or to polyploidy. 
Tetraploidy or polyploidy are characterized by whole extra 
sets of chromosomes, and arise in different conditions 
including cancer [39-41]. Tetraploid cells can originate 
from mitotic arrest/slippage, cytokinesis failure, or cell-
cell fusions which can result in genomic instability [41]. 
Importantly, we found an increased percentage of cells 
with chromosome 5 tetrasomy due to tetraploidy when 
RBMX was silenced during acute treatment with 
vemurafenib, suggesting that loss of function of this gene 
might play a crucial role in tetraploidization and 
exacerbates this phenotype. Also, the reduction of RBMX 
protein levels impacted on the down-regulation of 
phospho-AKT protein levels; these results might suggest 
the importance of RBMX protein not only to prevent DNA 
errors but also to inhibit AKT pathways which are 
fundamental to promote tumor cell survival and growth. 
However, further studies will be needed to determine 
mechanisms by which RBMX or RBM10 mutants affect 
chromosome 5 expansion and tetraploidization during 
treatment with BRAFV600E inhibitors. Overall, our results 
suggest the development of complex processes during 
sustained treatment with BRAFV600E inhibitors (i.e. 
vemurafenib) in the invasive spontaneously-immortalized 
PTC cells that we have exhaustively characterized: (i) 
initial presence of a heterogeneous tumor cell population 
including mainly diploid clones, but also aneuploid or 
tetraploid clones; (ii) gain of secondary mutations (i.e. in 
the RBM genes) permissive to chromosomal aberrations 
and tetraploidization; and (iii) selection and expansion of 
clones with advantageous aberrations (i.e. chromosome 5 
trisomy, gain of 1 copy of isochromosome 5p or 
tetraploidy). The spectrum of isochromosomes differed 
among neoplasms, e.g. +i5p has been proposed as one 
potential mechanism to drive tumor initiation and 
progression [42]. Although molecular mechanisms 
underlying the formation of isochromosomes are not yet 
well understood, our findings linking clone expansion of 
cells harboring 1 copy of isochromosome 5p (i.e. +5px1) 
in vemurafenib-resistant tumor cells might suggest that 
gene amplifications can occur in the presence of long-term 
treatment with vemurafenib as pro-survival response to 
tumor cells. RBMX elicits gene regulatory networks with 
cancer-associated genes of chromosome 5q but not of 5p. 
These networks represent top pathways of synergy in 
genetic interactions that control cell cycle checkpoints in 
response to DNA-damage and mechanisms of 
chromosome stability. Intriguingly, we did not find 
changes in growth rate in the resistant cells compared to 
the naïve cells. Importantly, we found a significant 
increase of resistant cells in G2-M phase. Since we did not 
find an increased growth rate of vemurafenib-resistant 
cells, we hypothesized that some tumor cell populations 
slowed down or blocked in G2/M phase, with an 
accumulation in this phase of the cell cycle. Also, our 
cytogenetic analysis revealed that tetraploid cells increased 
when BRAFV600E was inhibited by vemurafenib and 
RBMX was silenced. Collectively, these results suggest 
that vemurafenib-resistant cells enter cell cycle doubling 
their DNA content; however, they might not undergo to 
final cell division, resulting in an increase of tretraploidy. 
Loss of function of RBM genes (e.g. RBMX) and 
amplification of chromosome 5 genes in the vemurafenib-
resistant cells might contribute to cell cycle checkpoint 
dysfunctions. Ultimately, these complex biological 
processes which are evoked in vemurafenib-resistant cells 
might enhance mitotic errors, leading to tumor 
progression. Generally, PTC shows low frequency in 
somatic copy-number alterations compared to somatic 
mutations [1]. We analyzed the PTC TCGA data set [1]; 5p 
showed a trend in increase of copy-number (0.2 cutoff) 
from stage I (0%) to stage III (3.5%) in BRAFV600E-PTC, 
and from 1.03% in stage I to 13.04% in stage III in 
BRAFWT-PTC. BRAFWT-PTC showed copy-number gain 
in 5q similarly as observed for 5p; whereas 5q copy 
number did not change in BRAFV600E-PTC across all tumor 
stages. This result suggests that amplifications of 5q might 
be a sub-clonal event in BRAFV600E-PTC during sustained 
therapy with BRAFV600E inhibitors (e.g. vemurafenib). 
Vemurafenib has been recently used in patients with 
metastatic/refractory BRAFV600E-PTC and continuously 
administered twice a day in cycles of 28 days. This therapy 
showed anti-tumor activity with partial response in 10/26 
(38.5%, best overall response) patients. Four patients 
(15%) died after a median follow-up of 18.8 months [43]. 
These clinical findings indicate that inhibition of 
BRAFV600E is not effective in all metastatic BRAFV600E-
PTC patients and might be provocative for PTC cells to 
evoke complex mechanisms which escape this targeted/
precise therapy. Finding mutations which change the wild-
type functions in two genes which belong to the same 
family (i.e. RBMX and RBM10) and are involved in 
chromosomal segregation suggests that acquired 
secondary mutations may converge to allow or promote 
chromosome 5 copy number gain in resistant cells. This 
may be one of the possible mechanisms of resistance to 
BRAFV600E inhibitors in metastatic BRAFV600E-PTC. KTC1 
cells show also deletion of P16 loss which is frequent in 
many cancers and results in the over-activation of CDK4/6 
axis, critical to cell cycle entry [44]. Aberrant regulation of 
the cell cycle is one of the crucial mechanisms in tumor 
progression [45], which includes deregulation of 
checkpoints from G1 phase until mitosis [44]. Preclinical 
studies have shown that CDK4/6 inhibitors induce G1 
arrest of human cancer cell lines, suppressing tumor 
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growth or inducing tumor regression [46]. We have 
applied a combined therapeutic approach using, for the 
first time to the best of our knowledge, BRAFV600E and 
CDK4/6 inhibitors in human thyroid carcinoma cells. 
Remarkably, this combined therapy suppressed the clonal 
expansion of cells with aberrations of chromosome 5 (e.g. 
+i5px1). This treatment was able to induce apoptosis in 
both naïve and vemurafenib-resistant cells. Recently, it has 
been shown that vemurafenib-resistant melanoma cells 
were sensitive to the sustained exposure with palbociclib 
which determined cell senescence [47]. Also, combined 
therapy with BRAFV600E and CDK4/6 inhibitors was 
effective to prolong survival in mouse models for 
astrocytoma [48]. Although further studies will be 
necessary, our results suggest that targeting BRAFV600E and 
CDK4/6 in aggressive thyroid cancer can trigger apoptosis 
by overcoming CDK4/6-dependent cell cycle checkpoints 
dysfunctions which could allow or even lead to genomic 
instability. Genomic heterogeneity/instability might 
contribute significantly to BRAFV600E inhibitor treatment 
failure, suggesting that targeting different cancer-
associated pathways can be strength for long duration 
therapeutic responses. We also believe that orthogonal 
therapeutic approaches during treatment are required and 
fundamental to kill the majority of tumor cells at first with 
combined therapies. Our therapeutic approach was able to 
overcome both primary and secondary resistance to single 
agent treatments in invasive human thyroid carcinoma 
cells. It has been recently shown that KRAS G12D 
mutation can also be a genetic mechanism of secondary 
resistance to vemurafenib in KTC1 cells. Authors using a 
different therapeutic strategy found that subpopulation of 
KTC1 cells acquired resistance to this drug. However, 
these resistant cells became less sensitive to combined 
therapy with vemurafenib plus MEK1 or AKT inhibitors 
[49]. Therefore, single agent therapeutic interventions 
might reduce tumor cells number, but inadvertently 
provides powerful selective pressure for the expansion of 
resistant sub-clones. Clonal heterogeneity within tumors 
can be considered a substrate for evolutionary adaptation 
to the environment via Darwinian selection. The capacity 
of some subpopulations of tumor cells to survive in 
different environments is at the base of metastasis 
establishment and drugs resistance. Genetic divergence 
occurs during tumor progression, however, when selective 
pressures (e.g. drug treatments) are used, convergent 
evolution might occur. Our study is limited by the lack of 
human samples from clinical trials of patients with 
metastatic BRAFV600E-PTC treated with BRAFV600E 
inhibitors; however, our results are substantiated by our 
integrated ex-vivo approaches and applications of PTC 
TCGA patient-derived. It is also possible that transduction 
of RBMX or RBM10 mutants in vemurafenib-naïve PTC 
patient-derived cells might elicit more potent phenotypes 
than shRNA-mediated loss-of-function of the RBMXWT. 
In summary, we report for the first time that during 
vemurafenib therapy human invasive thyroid tumor 
cells with BRAFV600E and P16 loss acquired secondary 
resistance to this BRAFV600E inhibitor by amplification of 
chromosome 5, gain of the isochromosome 5p, tetrasomy 
5 due tetraploidy, and de novo mutations in the RBM 
genes family. Critically, our findings are translational and 
suggest that combined treatment with BRAFWT/V600E and 
CDK4/6 inhibitors could represent a novel therapeutic 
strategy to treat vemurafenib-resistant or vemurafenib-
naïve BRAFWT/V600E-PTC refractory to standard therapies. 
This combined therapy with vemurafenib plus palbociclib 
results in a very efficient strategy to target tumor cells 
either with primary or secondary resistance. The stable 
loss of P16 function in the background could represent 
a constraint that positively selects cell clones resistant 
to vemurafenib treatment due to the activation of P16 
downstream effectors such as CDK4/6. Our findings 
support the proof of concept that this combined therapy 
can be tested in a clinical trial of patients with metastatic 
BRAFWT/V600E-PTC or also with BRAFWT/V600E-ATC.
MATERIALS AND METHODS
Cell cultures
We used KTC1 (BRAFWT/V600E), TPC1 (BRAFWT/WT), 
8505c (BRAFV600E) and SW1736 (BRAFWT/V600E) human 
thyroid carcinoma cell lines. KTC1 is a spontaneously 
immortalized human thyroid carcinoma cell line which 
harbors BRAFWT/V600E mutation. It was established from 
the metastatic pleural effusion from a recurrent and 
radioiodine (RAI) refractory PTC in a 60-year-old male 
patient [50] by Dr. J. Kurebayashi (Department of Breast 
and Thyroid Surgery Kawasaki Medical School Kurashiki, 
Japan) and provided by Dr. Rebecca E. Schweppe 
(University of Colorado, USA). More details are reported 
in the Supplementary Methods. 
Drugs treatments
Vemurafenib (PLX4032, RG7204) (Selleckchem, 
Houston, TX, USA) was dissolved according to 
manufacturer’s  instructions in 100% dimethyl sulfoxide 
(DMSO, vehicle) (Sigma, USA) to achieve a stock 
concentration of 10 mM for in vitro assays. Palbociclib 
also named PD0332991 HCl (Selleckchem, USA) is an 
inhibitor of CDK4/6. Powder was dissolved in 100% 
DMSO (Sigma, USA) according to the manufactures 
instructions preparing 5 mM stocks. Intermediate doses of 
vemurafenib or palbociclib were prepared in 100% DMSO 
and diluted in 0.2% FBS high glucose DMEM in order 
to achieve the desired final concentrations maintaining 
a constant final concentration at 2% DMSO for optimal 
solubility (more details are reported in the Supplementary 
Oncotarget84757www.impactjournals.com/oncotarget
Methods). Combined treatments of vemurafenib plus 
palbociclib were calculated using Combenefit script [51] 
by MATLAB R2017a applying Bliss, Highest Single 
Agent (HSA), and Loewe methods in order to assess drug 
synergy and antagonism. Cells were treated for 48 hours 
in the presence of 0.2% FBS high glucose DMEM at final 
2% DMSO with: 1, 5 or 10 µM of either vemurafenib or 
palbociclib; or combined therapy with vemurafenib plus 
palbociclib combining all above doses. Vehicle was used 
as untreated control (2% DMSO diluted in 0.2% FBS high 
glucose DMEM). Before adding treatments, cells were 
washed with PBS from 10% FBS high glucose DMEM. 
Quantitative analysis was performed by direct count of 
adherent cells (magnification: 10×). Vehicle (control) was 
2% DMSO diluted in 0.2% FBS high glucose DMEM. 
Data were plotted applying a matrix of cell count using 
GraphPad Prism 6.
Model of resistance to vemurafenib therapy
In order to select KTC1 cells resistant to BRAFV600E 
inhibitor (vemurafenib), cells were treated with 10 µM 
vemurafenib for 12 (10 cycles, KTC1Res.1 cells) or 24 (20 
cycles, KTC1Res.2 cells) weeks. Cycle of therapy is defined 
as follows: treatment of cells with 10 µM vemurafenib in 
the presence of 0.2% FBS high glucose DMEM until 90% 
were dead cells and then recover them in 10% FBS high 
glucose DMEM without vemurafenib.
Exome sequencing
Mutation analysis for single nucleotide variants 
(SNV) was performed using MuTect v1.1.4 and annotated 
by Variant Effect Predictor (VEP) [52, 53]. Variants 
represented at >1% in either the African-American or 
European-American and not in COSMIC > 2x were 
considered to be likely germline and filtered out on the 
SNV/indel report. Somatic genetic variants which showed 
an allelic fraction greater than 30% were considered 
for variant calling passing criteria to exclude technical 
artifacts, including removal of variants located at the last 
mapped base (or outside) of amplicon target regions and 
variants with the majority of supporting reads harboring 
excess additional mismatches or indels (likely sequencing 
error). More details are reported in the Supplementary 
Methods.
Cytogenetic analysis
Cytogenetic analysis of metaphases was performed 
on cultured thyroid carcinoma cell lines (KTC1Naive, 
KTC1Res.1, KTC1Res.2, and SW1736) using standard 
techniques (Beth Israel Deaconess Medical Center, 
Boston, MA). GTG (G-banding by Trypsin treatment 
followed by Giemsa stain) banded metaphases were 
obtained using established harvesting and banding 
techniques.
Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) was 
performed with Abbott Molecular probes (Abbott 
Molecular, Des Plaines, IL) following the manufacturer’s 
recommended protocol. 200 interphase cells were scored 
for each probe hybridization for each thyroid carcinoma 
cell line. 
Affymetrix CytoScan HD oligonucleotide-SNP 
microarray
Affymetrix CytoScan HD array (Affymetrix, Santa 
Clara, CA) was used to identify chromosomal gains and 
losses and their breakpoints using DNA from the same 
thyroid carcinoma cell cultures used in the cytogenetic 
analysis. Microarray analysis was performed according 
to the manufacturer’s protocol. Each sample was digested 
with NspI, ligated to adaptors, and amplified with 
PCR. The PCR product was purified using a magnetic 
separation technique, fragmented, and labeled before 
hybridization to the microarray. The oligo-SNP (single 
nucleotide polymorphism) array contains approximately 
2.67 million probes, including 1.9 million copy number 
probes and 750,000 SNP probes. Copy number alterations 
were analyzed using Chromosome Analysis Suite (ChAS) 
software (Affymetrix). The gene content of the duplicated 
and deleted regions was obtained from the UCSC Genome 
Browser and the NCBI database.
Gene regulatory networks and pathways analysis 
in human PTC samples
We downloaded clinical and RNA-seq data of PTC 
from TCGA website and used edgeR package in R to get 
differentially expressed genes using 234 BRAFV600E-PTC 
and 255 BRAFWT-PTC samples. Genes with p-value less 
than 0.05 were considered differentially expressed and 
statistically significant. WGCNA (weighted correlation 
network analysis) was used to build a network between 
differentially expressed genes obtained from BRAFV600E-
PTC versus BRAFWT-PTC TCGA on the basis of 
coexpression information of genes. More details are 
reported in the Supplementary Methods.
Statistical analysis
Statistical analysis was carried out using GraphPad 
Prism 6 software (San Diego, CA, USA), SAS/STAT(R) 
9.2, and Microsoft Excel (Boston, MA, USA) statistical 
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tools. T-student, one-way analysis of variance (ANOVA) 
using Tukey’s correction for multiple comparisons, 
Fisher’s exact, slope analysis (angular coefficient, 
m-value), Mantel-Haenszel (M-H), and chi-square tests 
were used. Data are reported as the averaged value, and 
error bars represent the standard deviation of the average 
for each group. Results with p values below 0.05 were 
considered statistically significant. 
We also used western blotting, cell cycle, cell 
viability, cell growth, apoptosis, and viral transduction 
(for gene knockdown) assays; and gene regulatory 
networks/pathways analyses (for more details, see the 
Supplementary Methods).
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